Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for argenex SE (ARGX : NSDQ)
 
 • Company Description   
argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.

Number of Employees: 1,599

 
 • Price / Volume Information   
Yesterday's Closing Price: $543.48 Daily Weekly Monthly
20 Day Moving Average: 377,137 shares
Shares Outstanding: 61.06 (millions)
Market Capitalization: $33,184.65 (millions)
Beta: 0.37
52 Week High: $678.21
52 Week Low: $432.96
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -7.24% -11.37%
12 Week -6.45% -20.09%
Year To Date -11.63% -17.23%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
LAARDERHOOGTWEG 25
-
AMSTERDAM,P7 1101EB
NLD
ph: 31-10-703-8441
fax: -
aroy@argenx.com http://www.argenx.com
 
 • General Corporate Information   
Officers
Tim Van Hauwermeiren - Chief Executive Officer and Director
Karen Massey - Chief Operating Officer
Karl Gubitz - Chief Financial Officer
Arjen Lemmen - Vice-President Corporate Development & Strategy
Werner Lanthaler - Director

Peer Information
argenex SE (CORR.)
argenex SE (RSPI)
argenex SE (CGXP)
argenex SE (BGEN)
argenex SE (GTBP)
argenex SE (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04016X101
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/24/25
Share - Related Items
Shares Outstanding: 61.06
Most Recent Split Date: (:1)
Beta: 0.37
Market Capitalization: $33,184.65 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $3.39 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $12.77 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 43.23% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/24/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 42.56
Trailing 12 Months: 90.58
PEG Ratio: 0.98
Price Ratios
Price/Book: 6.01
Price/Cash Flow: 182.96
Price / Sales: 12.54
EPS Growth
vs. Year Ago Period: 348.08%
vs. Previous Quarter: 63.29%
Sales Growth
vs. Year Ago Period: 95.72%
vs. Previous Quarter: 6.06%
ROE
06/30/25 - -
03/31/25 - 16.15
12/31/24 - 6.68
ROA
06/30/25 - -
03/31/25 - 14.33
12/31/24 - 5.93
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 7.29
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 6.68
Operating Margin
06/30/25 - -
03/31/25 - 14.89
12/31/24 - 7.24
Net Margin
06/30/25 - -
03/31/25 - 40.20
12/31/24 - 36.99
Pre-Tax Margin
06/30/25 - -
03/31/25 - 13.67
12/31/24 - 3.78
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - 90.49
Inventory Turnover
06/30/25 - -
03/31/25 - 1.44
12/31/24 - 1.24
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©